Epidemiology and treatment of post-stroke depression

Paolucci, Stefano

doi:10.2147/ndt.s2017

Cited by 214 publications

(170 citation statements)

References 92 publications

Supporting

Mentioning

163

Contrasting

Unclassified

Order By: Relevance

“…According to epidemiological studies, nearly 30% of stroke patients develop depression, either in the early or in the late stages after stroke. Somatic symptoms like psychomotor retardation, and disturbances in appetite, sleep, and sexual interest, depression are commonly observed problems (6,20). In our study, 10% of the patient's depression status was normal, but the others had different level of depression.…”

Section: Discussionsupporting

confidence: 42%

See 1 more Smart Citation

Examination of Sleep Quality, Anxiety and Depression in Stroke Patients

Hüzmeli¹,

Sarac²

2017

Türk Beyin Damar Hast Derg

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 42%

“…Post-stroke depression affects disability level, cognitive status and vice versa. The frequency of major depression seems to increase during the first year (4,5,6,7).…”

Section: Introductionmentioning

confidence: 99%

Examination of Sleep Quality, Anxiety and Depression in Stroke Patients

Hüzmeli¹,

Sarac²

2017

Türk Beyin Damar Hast Derg

View full text Add to dashboard Cite

“…This result could be associated with the common occurrence of depression among patients after stroke or those with coronary heart disease (27,28).…”

Section: Tab 2 the Univariate Analysis Of The Infl Uence Of Patientmentioning

confidence: 99%

The use of antiplatelet medication in hospitalised elderly patients

Wawruch¹,

Slezakova²,

Murı́n³

et al. 2015

BLL

View full text Add to dashboard Cite

BACKGROUND: The use of antiplatelet agents is strongly recommended for the secondary prevention of ischemic events such as myocardial infarction, stroke/transient ischemic attack (TIA). OBJECTIVES: The aim of our study was to analyse the use of antiplatelet medication in patients after myocardial infarction, stroke/TIA, and patients with both conditions and to identify patient-related characteristics, which determine the use of such drugs in elderly patients. METHODS: Study sample (n = 372) was derived from 2,157 patients admitted to long-term care departments of three municipal hospitals. The study included patients aged ≥65 years after myocardial infarction, stroke/TIA or both. RESULTS: Antiplatelet medications were prescribed in 54.8 % and 68.5 % of patients at hospital admission and discharge, respectively. Hospitalisation led to a signifi cant increase in the use of antiplatelet medication in patients after myocardial infarction and in those with the combination of both events. However, in patients after only stroke/TIA, we did not fi nd any signifi cant difference comparing the use of antiplatelet medication at the time of hospital admission and discharge, respectively. CONCLUSION: Our study revealed that physicians are more aware of the benefi ts of antiplatelet medication in elderly patients after myocardial infarction or those after both myocardial infarction and stroke/TIA in comparison with patients after only stroke/TIA (Tab. 3, Ref. 32). Text in PDF www.elis.sk.

show abstract

“…In fact, approximately 30 to 40% of stroke survivors will experience clinically significant depression during the first year after stroke 139 and at some point following a stroke 140,141 . Over half of these patients will develop major or minor depression in the acute care rehabilitation settings 142 .…”

Section: Mdd In the Rehabilitation Settingmentioning

confidence: 99%

“…A recent study showed that ten to 15 sessions of rTMS applied on the left DLPFC at a frequency of 10Hz, and an intensity of 110% MT was associated with significant reduction of depressive symptoms by 30% and a remission rate of 10% as compared to placebo intervention. Mild and few adverse effects such as headache were reported [131][132][133][134][135][136][137][138][139][140][141][142][143][144][145][146][147][148][149] . Another advantage of the use of rTMS is the improvement in executive functions by rTMS 150,151 .…”

Section: Mdd In the Rehabilitation Settingmentioning

confidence: 99%

Neuromodulation approaches for the treatment of major depression: challenges and recommendations from a working group meeting

Brunoni

Teng

Correa³

et al. 2010

Arq. Neuro-Psiquiatr.

View full text Add to dashboard Cite

The use of neuromodulation as a treatment for major depressive disorder (MDD) has recently attracted renewed interest due to development of other non-pharmacological therapies besides electroconvulsive therapy (ECT) such as transcranial magnetic stimulation (TMS), transcranial direct current stimulation (tDCS), deep brain stimulation (DBS), and vagus nerve stimulation (VNS). Method: We convened a working group of researchers to discuss the updates and key challenges of neuromodulation use for the treatment of MDD. results: The state-of-art of neuromodulation techniques was reviewed and discussed in four sections: [1] epidemiology and pathophysiology of MDD; [2] a comprehensive overview of the neuromodulation techniques; [3] using neuromodulation techniques in MDD associated with non-psychiatric conditions; [4] the main challenges of neuromodulation research and alternatives to overcome them. Discussion: ECT is the first-line treatment for severe depression. TMS and tDCS are strategies with a relative benign profile of side effects; however, while TMS effects are comparable to antidepressant drugs for treating MDD; further research is needed to establish the role of tDCS. DBS and VNS are invasive strategies with a possible role in treatment-resistant depression. In summary, MDD is a chronic and incapacitating condition with a high prevalence; therefore clinicians should consider all the treatment options including invasive and non-invasive neuromodulation approaches. Key words: comprehensive review, major depressive disorder, ECT, TMS, clinical guidelines.Estratégias de neuromodulação para o tratamento da depressão maior: desafios e recomendações de uma força-tarefa rEsuMo O uso de técnicas de neuromodulação para o tratamento do transtorno depressivo maior (TDM) tem despertado um renovado interesse nos últimos anos com o desenvolvimento de outras intervenções não-farmacólogicas além da eletroconvulsoterapia (ECT), como a estimulação magnética transcraniana (EMT), a estimulação transcraniana por corrente continua (ETCC), a estimulação cerebral profunda (DBS) e a estimulação de nervo vago (VNS). Método: Nós organizamos um grupo de trabalho com vários pesquisadores para discutir os avanços recentes e os principais desafios para o uso da neuromodulação no tratamento os principais desafios da pesquisa na neuromodulação e alternativas para superá-los. Discussão: ECT é o tratamento de primeira linha para depressão grave. EMT e ETCC são estratégias com um perfil benigno de efeitos adversos; contudo, enquanto os efeitos da EMT são comparáveis ao das drogas antidepressivas para o tratamento da TDM, a eficácia da ETCC ainda precisa ser estabelecida por mais pesquisas clínicas. DBS e VNS são intervenções invasivas com um papel possível para a depressão refratária. Em resumo, TDM é uma condição crônica, incapacitante e de alta prevalência; portanto na prática clínica todas as opções de tratamento possíveis, incluindo as farmacológicas e não-farmacológicas, devem ser consideradas. Palavras-chave: artigo de revisão, tra...

show abstract

Epidemiology and treatment of post-stroke depression

Cited by 214 publications

References 92 publications

Examination of Sleep Quality, Anxiety and Depression in Stroke Patients

Examination of Sleep Quality, Anxiety and Depression in Stroke Patients

The use of antiplatelet medication in hospitalised elderly patients

Neuromodulation approaches for the treatment of major depression: challenges and recommendations from a working group meeting

Contact Info

Product

Resources

About